STOCK TITAN

CDNA (CDNA) insider Peter Maag discloses 7,000-share planned sale and recent trades

(Neutral)
(Neutral)
Form Type
144

Rhea-AI Filing Summary

CDNA insider Peter Maag filed to sell 7,000 shares of common stock through Morgan Stanley Smith Barney LLC Executive Financial Services, with an indicated value of $329,505.40 on NASDAQ. The shares relate to restricted stock granted as compensation on 04/11/2023, 01/29/2024, and 02/03/2024. The filing also lists several recent sales, including 7,000 shares for $333,851.00 on 08/11/2026 and 75,653 shares for $3,576,851.19 on 08/04/2026.

Positive

  • None.

Negative

  • None.
Planned shares to be sold 7,000 shares Common stock to be sold through Morgan Stanley Smith Barney LLC Executive Financial Services
Planned sale value $329,505.40 Indicated value of 7,000 shares of common stock on NASDAQ
Recent sale 08/11/2026 7,000 shares for $333,851.00 Common stock sale by Peter Maag
Recent sale 08/04/2026 75,653 shares for $3,576,851.19 Common stock sale by Peter Maag
Restricted stock grant 01/29/2024 3,797 shares Restricted stock from issuer listed as compensation
Restricted stock grant 04/11/2023 1,256 shares Restricted stock from issuer listed as compensation
Restricted stock grant 02/03/2024 1,947 shares Restricted stock from issuer listed as compensation
Restricted Stock financial
"Common | 01/29/2024 | Restricted Stock | Issuer"
Shares granted to an individual that carry limits on transfer or sale until certain conditions are met, such as staying with the company for a set time or hitting performance targets. Think of them as a locked gift that gradually opens; for investors they matter because they affect how many shares may enter the market later, signal management incentives and potential dilution, and reveal confidence in future company performance.
Compensation financial
"3797 | 01/29/2024 | Compensation Common | 04/11/2023"
Executive Financial Services financial
"Morgan Stanley Smith Barney LLC Executive Financial Services 1 New York Plaza"

FAQ

What does CDNA’s Form 144 filing by Peter Maag disclose?

The filing shows Peter Maag plans to sell 7,000 CDNA common shares via Morgan Stanley Smith Barney LLC Executive Financial Services, with an indicated value of $329,505.40, and lists several recent open-market sales of CDNA shares.

How many CDNA shares is Peter Maag planning to sell under this Form 144?

Peter Maag is planning to sell 7,000 shares of CDNA common stock. The filing lists these shares with an aggregate value of $329,505.40 and identifies Morgan Stanley Smith Barney LLC Executive Financial Services as the broker handling the transaction.

Which recent CDNA stock sales by Peter Maag are reported in the Form 144?

Reported recent CDNA sales include 7,000 shares for $333,851.00 on 08/11/2026 and 75,653 shares for $3,576,851.19 on 08/04/2026, along with several other transactions in August 2026, each with specified share counts and dollar amounts.

What is the source of the CDNA shares in Peter Maag’s Form 144 filing?

The shares trace to restricted stock granted as compensation by the issuer. The filing lists awards dated 04/11/2023 (1,256 shares), 01/29/2024 (3,797 shares), and 02/03/2024 (1,947 shares) as securities to be sold.

Which broker is handling Peter Maag’s planned CDNA share sale?

The planned sale of 7,000 CDNA shares is through Morgan Stanley Smith Barney LLC Executive Financial Services, located at 1 New York Plaza, 8th Floor, New York, NY 10004, as specified in the Form 144 filing.

On which market are Peter Maag’s CDNA shares listed according to the Form 144?

The shares referenced in the filing are listed on NASDAQ. The Form 144 indicates NASDAQ as the trading market for the CDNA common stock that Peter Maag has sold recently and plans to sell.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Learn about SEC filing dates

144: Filer Information

144: Issuer Information

144: Securities Information



Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold


* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.



Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

144: Remarks and Signature